comprehensive -WSS

comprehensive

author：focus 2025-10-02 00:29:12 - browse：5218

Eli Lilly said Friday it will acquire Versanis Bio, a private company developing an obesity drug that specifically targets fat mass, as the race among pharmaceutical companies to offer weight loss medications intensifies.

The deal indicates Lilly is aiming to diversify its growing portfolio of weight loss therapies, as Versanis’ drug employs an entirely different mechanism than the existing obesity drugs that Lilly is studying. The pharma giant didn’t say how much it would pay Versanis upfront, but said that if the drug meets certain milestones, the total payment could reach $1.9 billion.

Lilly, along with other pharma companies like Novo Nordisk, has been developing products in the class of GLP-1 drugs, which mimic the glucagon-like peptide 1 hormone that helps people feel full. These drugs – including Novo’s Ozempic and Wegovy, and Lilly’s Mounjaro – have exploded in popularity because they lead to significant weight loss.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Bright Health sells Medicare Advantage business to Molina
Next article： Ultragenyx gene therapy for rare liver ailment succeeds in late

WSS

Change Healthcare cyberattack affects 25% of CVS/Aetna insurance claims

For AI in health care standards, federal regulators join with industry group

ASCO: AstraZeneca says CAR

He's 19 months old and has one of the world’s rarest diseases

BMI, flaws aside, is found to be useful estimate of body fat in youth

Cord blood banking comes at a high cost to babies

explore

comprehensive

focus

George Santos makes 1st court appearance after pleading not guilty to 13 counts

ASCO: AstraZeneca says CAR

Drug repurposing or repositioning? The language matters

Change Healthcare can notify patients about the breach, HHS says

Sports medicine is finally prioritizing gender equality

At ASCO, pharma leaders speak of advances in 'smart bomb' drugs

Virginia high school admissions case could be legal follow

Why Talkspace is targeting Medicare, a tricky market

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

HIV drugs protect against transmission, even in unprotected sex

focus

Ultragenyx gene therapy for rare liver ailment succeeds in late

Ultragenyx gene therapy for rare liver ailment succeeds in late

How to increase colonoscopy rates? Looks like an AI can help

State of the Union pitch: Bigger Medicare drug price negotiations

Microsoft's Peter Lee: Generative AI could help doctors be more human

He's 19 months old and has one of the world’s rarest diseases

hotspot

explore

hotspot

focus